Log in

NASDAQ:TMDX - TransMedics Group Stock Price, Forecast & News

-1.13 (-8.77 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
Now: $11.76
50-Day Range
MA: $15.94
52-Week Range
Now: $11.76
Volume145,800 shs
Average Volume169,883 shs
Market Capitalization$249.55 million
P/E RatioN/A
Dividend YieldN/A
TransMedics, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), an integrated, compact, portable preservation technology that addresses unmet need for organs for transplantation. Its Organ Care System preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure. Its Organ Care System incudes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains organs in a near physiologic state and enables surgeons to perfuse and ventilate the organ between the donor and recipient sites; OCS Heart, a portable heart perfusion system that helps to maintain organs in a warm functioning state outside of the body; and OCS Liver, a portable perfusion and monitoring system that maintains organs in a near physiologic state. The company offers its products in the United States and internationally. TransMedics, Inc. is headquartered in Andover, Massachusetts. TransMedics, Inc. is a subsidiary of Transmedics Group, Inc.
Read More

Industry, Sector and Symbol

Industry Electromedical equipment
Current SymbolNASDAQ:TMDX



Sales & Book Value

Annual Sales$23.60 million
Book Value$2.58 per share


Net Income$-33,550,000.00
Net Margins-142.12%


Market Cap$249.55 million
Next Earnings Date6/10/2020 (Estimated)
OptionableNot Optionable

Receive TMDX News and Ratings via Email

Sign-up to receive the latest news and ratings for TMDX and its competitors with MarketBeat's FREE daily newsletter.

TransMedics Group (NASDAQ:TMDX) Frequently Asked Questions

How has TransMedics Group's stock been impacted by COVID-19 (Coronavirus)?

TransMedics Group's stock was trading at $13.62 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TMDX stock has decreased by 13.7% and is now trading at $11.76. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of TransMedics Group?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for TransMedics Group.

When is TransMedics Group's next earnings date?

TransMedics Group is scheduled to release its next quarterly earnings announcement on Wednesday, June 10th 2020. View our earnings forecast for TransMedics Group.

How were TransMedics Group's earnings last quarter?

TransMedics Group Inc (NASDAQ:TMDX) issued its earnings results on Monday, March, 2nd. The company reported ($0.43) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.39) by $0.04. The company earned $6.06 million during the quarter, compared to analyst estimates of $6.51 million. View TransMedics Group's earnings history.

What guidance has TransMedics Group issued on next quarter's earnings?

TransMedics Group updated its FY 2020 After-Hours earnings guidance on Monday, March, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $40-43 million, compared to the consensus revenue estimate of $46.81 million.

What price target have analysts set for TMDX?

4 brokers have issued 12-month price objectives for TransMedics Group's shares. Their forecasts range from $16.00 to $37.00. On average, they expect TransMedics Group's stock price to reach $28.75 in the next year. This suggests a possible upside of 144.5% from the stock's current price. View analysts' price targets for TransMedics Group.

Has TransMedics Group been receiving favorable news coverage?

Media coverage about TMDX stock has been trending somewhat positive recently, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. TransMedics Group earned a coverage optimism score of 1.8 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View the latest news aboutTransMedics Group.

Are investors shorting TransMedics Group?

TransMedics Group saw a decline in short interest in February. As of February 14th, there was short interest totaling 1,420,000 shares, a decline of 10.1% from the January 30th total of 1,580,000 shares. Based on an average trading volume of 197,600 shares, the days-to-cover ratio is presently 7.2 days. Approximately 11.5% of the company's shares are short sold. View TransMedics Group's Current Options Chain.

Who are some of TransMedics Group's key competitors?

What other stocks do shareholders of TransMedics Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Gilead Sciences (GILD), Roku (ROKU), AbbVie (ABBV), AT&T (T), Advanced Micro Devices (AMD), Etsy (ETSY), NVIDIA (NVDA), Walt Disney (DIS), IBM (IBM) and Exxon Mobil (XOM).

Who are TransMedics Group's key executives?

TransMedics Group's management team includes the following people:
  • Dr. Waleed H. Hassanein, Pres, CEO & Director (Age 51)
  • Mr. Stephen Gordon, CFO, Treasurer & Sec. (Age 51)
  • Mr. John F. Carey, VP of Operations (Age 55)
  • Mr. Ike Okonkwo, VP of Fin. & Accounting (Age 48)
  • Mr. Brian Thomson, VP of HR (Age 51)

When did TransMedics Group IPO?

(TMDX) raised $75 million in an initial public offering on Thursday, May 2nd 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

What is TransMedics Group's stock symbol?

TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX."

Who are TransMedics Group's major shareholders?

TransMedics Group's stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), Credit Suisse AG (5.35%), Sandhill Capital Partners LLC (3.48%), Emerald Advisers LLC (2.13%), Emerald Mutual Fund Advisers Trust (2.03%) and Roubaix Capital LLC (1.25%). Company insiders that own TransMedics Group stock include David Weill, Edwin M Kania Jr and Tamer I Khayal. View institutional ownership trends for TransMedics Group.

Which major investors are buying TransMedics Group stock?

TMDX stock was acquired by a variety of institutional investors in the last quarter, including Credit Suisse AG, Emerald Advisers LLC, Sandhill Capital Partners LLC, Emerald Mutual Fund Advisers Trust, State Street Corp, Roubaix Capital LLC, Geode Capital Management LLC, and Oregon Public Employees Retirement Fund. Company insiders that have bought TransMedics Group stock in the last two years include David Weill, and Edwin M Kania Jr. View insider buying and selling activity for TransMedics Group.

How do I buy shares of TransMedics Group?

Shares of TMDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is TransMedics Group's stock price today?

One share of TMDX stock can currently be purchased for approximately $11.76.

How big of a company is TransMedics Group?

TransMedics Group has a market capitalization of $249.55 million and generates $23.60 million in revenue each year. The company earns $-33,550,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis.  View additional information about TransMedics Group.

What is TransMedics Group's official website?

The official website for TransMedics Group is http://www.transmedics.com/.

How can I contact TransMedics Group?

TransMedics Group's mailing address is 200 MINUTEMAN ROAD, ANDOVER MA, 01810. The company can be reached via phone at 978-552-0900 or via email at [email protected]

MarketBeat Community Rating for TransMedics Group (NASDAQ TMDX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  39 (Vote Outperform)
Underperform Votes:  45 (Vote Underperform)
Total Votes:  84
MarketBeat's community ratings are surveys of what our community members think about TransMedics Group and other stocks. Vote "Outperform" if you believe TMDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TMDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Featured Article: Analyst Ratings Trading

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel